Antimalarials: Pre-Clinical development update

Recepta biopharma portfolio: clinical and pre clinical development

ReceptaBiopharma is a Brazilian Biotechnology company dedicated to the research and development of monoclonal antibodies and peptides as therapeutic agents for treatment of cancer. Monoclonal antibodies (mAbs) recognize specific targets on the surface of cells, or secreted signaling molecules, and can work as anti-tumor agents by inducing tumor cell death. MAbs act by targeting the tumor cells ...

Synthetic Antimalarials

Marine Antimalarials

Malaria is an infectious disease causing at least 1 million deaths per year, and, unfortunately, the chemical entities available to treat malaria are still too limited. In this review we highlight the contribution of marine chemistry in the field of antimalarial research by reporting the most important results obtained until the beginning of 2009, with particular emphasis on recent discoveries....

Update on the clinical development of candidate malaria vaccines.

The recent availability of significantly increased levels of funding for unmet medical needs in the developing world, made available by newly created public-private-partnerships, has proven to be a powerful driver for stimulating clinical development of candidate vaccines for malaria. This new way forward promises to greatly increase the likelihood of bringing a safe and effective vaccine to li...

Clinical Update

The scapulothoracic interface is made up of the anterior surface of the scapula and the posterior aspect of the thoracic cage. This space is occupied primarily by myofascial components. Upper extremity motion requires the movement of the scapula on the thoracic cage. To decrease friction between these two structures, the interface is lubricated by a serious fluid. Adhesions formation due to any...